Advertisement

Cellular Models: HD Patient-Derived Pluripotent Stem Cells

  • Charlene Geater
  • Sarah Hernandez
  • Leslie Thompson
  • Virginia B. Mattis
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1780)

Abstract

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by expanded polyglutamine (polyQ)-encoding repeats in the Huntingtin (HTT) gene. Traditionally, HD cellular models consisted of either patient cells not affected by disease or rodent neurons expressing expanded polyQ repeats in HTT. As these models can be limited in their disease manifestation or proper genetic context, respectively, human HD pluripotent stem cells (PSCs) are currently under investigation as a way to model disease in patient-derived neurons and other neural cell types. This chapter reviews embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) models of disease, including published differentiation paradigms for neurons and their associated phenotypes, as well as current challenges to the field such as validation of the PSCs and PSC-derived cells. Highlighted are potential future technical advances to HD PSC modeling, including transdifferentiation, complex in vitro multiorgan/system reconstruction, and personalized medicine. Using a human HD patient model of the central nervous system, hopefully one day researchers can tease out the consequences of mutant HTT (mHTT) expression on specific cell types within the brain in order to identify and test novel therapies for disease.

Keywords

Huntington’s disease (HD) Huntingtin (HTT) Induced pluripotent stem cell (iPSC) Embryonic stem cell (ESC) Striatum Modeling Differentiation 

Notes

Acknowledgment

Charlene Geater and Sarah Hernandez contributed equally to this work.

References 

  1. 1.
    The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971CrossRefGoogle Scholar
  2. 2.
    Myers RH (2004) Huntington’s disease genetics. NeuroRx 1:255PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Duyao M, Ambrose C, Myers R et al (1993) Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 4:387PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Bird ED, Caro AJ, Pilling JB (1974) A sex related factor in the inheritance of Huntington’s chorea. Ann Hum Genet 37:255PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Myers RH, Sax DS, Schoenfeld M et al (1985) Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 48:530PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Trottier Y, Biancalana V, Mandel J-L (1994) Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. J Med Genet 31:377PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length. Nat Genet 4:398–403PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Wexler NS, Lorimer J, Porter J et al (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci U S A 101:3498PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Gusella J, MacDonald M (2002) No post-genetics era in human disease research. Nat Rev Genet 3:72PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Graveland G, Williams R, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227:770PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kemp JM, Powell T (1971) The structure of the caudate nucleus of the cat: light and electron microscopy. Philos Trans R Soc Lond B Biol Sci 262:383PubMedCrossRefGoogle Scholar
  12. 12.
    Yager L, Garcia A, Wunsch A et al (2015) The ins and outs of the striatum: role in drug addiction. Neuroscience 301:529PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Vonsattel J-P, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Nasir J, Floresco SB, O’Kusky JR et al (1995) Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811PubMedCrossRefGoogle Scholar
  15. 15.
    Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300PubMedCrossRefGoogle Scholar
  16. 16.
    Duyao MP, Auerbach AB, Ryan A et al (1995) Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269:407PubMedCrossRefGoogle Scholar
  17. 17.
    Zeitlin S, Liu J-P, Chapman DL et al (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet 11:155PubMedCrossRefGoogle Scholar
  18. 18.
    Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89:910PubMedCrossRefGoogle Scholar
  19. 19.
    Zheng Z, Diamond MI (2012) Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci 107:189PubMedCrossRefGoogle Scholar
  20. 20.
    Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington’s disease. Nature 448:704PubMedCrossRefGoogle Scholar
  21. 21.
    Ochaba J, Lukacsovich T, Csikos G et al (2014) Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A 111:16889PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Cuervo AM, Zhang S (2015) Selective autophagy and Huntingtin: learning from disease. Cell Cycle 14:1617PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Zheng S, Clabough EB, Sarkar S et al (2010) Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet 6:e1000838PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Zuccato C, Cattaneo E (2014) Huntington’s disease. Handb Exp Pharmacol 220:357PubMedCrossRefGoogle Scholar
  26. 26.
    Zhao X, Chen XQ, Han E, Hu Y, Paik P, Ding Z, Overman J, Lau AL, Shahmoradian SH, Chiu W, Thompson LM, Wu C, Mobley WC (2016) TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington’s disease. Proc Natl Acad Sci U S A 113:38Google Scholar
  27. 27.
    Rigamonti D, Bauer JH, De-Fraja C et al (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705PubMedCrossRefGoogle Scholar
  28. 28.
    Ho LW, Brown R, Maxwell M et al (2001) Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington’s disease. J Med Genet 38:450PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Leavitt BR, van Raamsdonk JM, Shehadeh J et al (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96:1121PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang Y, Leavitt BR, van Raamsdonk JM et al (2006) Huntingtin inhibits caspase-3 activation. EMBO J 25:5896PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Ona VO, Li M, Vonsattel JPG et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399:263PubMedCrossRefGoogle Scholar
  32. 32.
    Gafni J, Ellerby LM (2002) Calpain activation in Huntington’s disease. J Neurosci 22:4842PubMedCrossRefGoogle Scholar
  33. 33.
    Sanchez I, Xu C-J, Juo P et al (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623PubMedCrossRefGoogle Scholar
  34. 34.
    Cisbani G, Cicchetti F (2012) An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 3:e382PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Gauthier LR, Charrin BC, Borrell-Pagès M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127PubMedCrossRefGoogle Scholar
  36. 36.
    Liot G, Zala D, Pla P et al (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33:6298PubMedCrossRefGoogle Scholar
  37. 37.
    Hu S, Zhao MT, Jahanbani F et al (2016) Effects of cellular origin on differentiation of human induced pluripotent stem cell-derived endothelial cells. JCI Insight 1. pii: e85558Google Scholar
  38. 38.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145CrossRefGoogle Scholar
  39. 39.
    Verlinsky Y, Strelchenko N, Kukharenko V et al (2005) Human embryonic stem cell lines with genetic disorders. Reprod Biomed Online 10:105PubMedCrossRefGoogle Scholar
  40. 40.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663PubMedCrossRefGoogle Scholar
  41. 41.
    Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917CrossRefGoogle Scholar
  43. 43.
    Fusaki N, Ban H, Nishiyama A et al (2009) Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85:348PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Stadtfeld M, Nagaya M, Utikal J et al (2008) Induced pluripotent stem cells generated without viral integration. Science 322:945PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Hanna J, Wernig M, Markoulaki S et al (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Okita K, Hong H, Takahashi K et al (2010) Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 5:418PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Anokye-Danso F, Trivedi CM, Juhr D et al (2011) Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8:376PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Zhou H, Wu S, Joo JY et al (2009) Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4:381PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Huangfu D, Osafune K, Maehr R et al (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26:1269PubMedCrossRefGoogle Scholar
  50. 50.
    Cahan P, Daley GQ (2013) Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 14:357PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Lister R, Pelizzola M, Kida YS et al (2011) Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471:68PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Mertens J, Marchetto MC, Bardy C et al (2016) Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat Rev Neurosci 17:424PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Trounson A, DeWitt ND (2016) Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 17:194PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Ouimet CC, Miller PE, Hemmings HC et al (1984) DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions: III. Immunocytochemical localization. J Neurosci 4:111PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Ivkovic S, Ehrlich ME (1999) Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 19:5409PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Ivkovic S, Polonskaia O, Fariñas I et al (1997) Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience 79:509PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    El-Akabawy G, Medina LM, Jeffries A et al (2011) Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway. Stem Cells Dev 20:1873PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Aubry L, Bugi A, Lefort N et al (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 105:e16707CrossRefGoogle Scholar
  60. 60.
    Jeon I, Lee N, Li JY et al (2012) Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells. Stem Cells 30:2054PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Joannides AJ, Fiore-Heriche C, Battersby AA et al (2007) A scaleable and defined system for generating neural stem cells from human embryonic stem cells. Stem Cells 25:731PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Danjo T, Eiraku M, Muguruma K et al (2011) Subregional specification of embryonic stem cell-derived ventral telencephalic tissues by timed and combinatory treatment with extrinsic signals. J Neurosci 31:1919PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Zhang N, An MC, Montoro D et al (2010) Characterization of human Huntington’s disease cell model from induced pluripotent stem cells. PLoS Curr 2:RRN1193PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Ma L, Hu B, Liu Y et al (2012) Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 10:455PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Delli Carri A, Onorati M, Lelos MJ et al (2013) Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 140:301PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Delli Carri A, Onorati M, Castiglioni V et al (2013) Human pluripotent stem cell differentiation into authentic striatal projection neurons. Stem Cell Rev 9:461PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Chambers SM, Fasano CA, Papapetrou EP et al (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Arber C, Precious SV, Cambray S et al (2015) Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development 142:1375PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Nekrasov ED, Vigont VA, Klyushnikov SA et al (2016) Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener 11:27PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Arlotta P, Molyneaux BJ, Jabaudon D et al (2008) Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J Neurosci 28:622PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    The HD iPSC Consortium (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264CrossRefGoogle Scholar
  72. 72.
    Shin E, Palmer MJ, Li M et al (2012) GABAergic neurons from mouse embryonic stem cells possess functional properties of striatal neurons in vitro, and develop into striatal neurons in vivo in a mouse model of Huntington’s disease. Stem Cell Rev 8:513PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Tapscott SJ, Davis RL, Thayer MJ et al (1988) MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242:405PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Berninger B, Costa MR, Koch U et al (2007) Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. J Neurosci 27:8654PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Heinrich C, Blum R, Gascón S et al (2010) Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol 8:e1000373PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Zhang Y, Pak C, Han Y et al (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78:785PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Vierbuchen T, Ostermeier A, Pang ZP et al (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Pfisterer U, Wood J, Nihlberg K et al (2011) Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle 10:3311PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Pang ZP, Yang N, Vierbuchen T et al (2011) Induction of human neuronal cells by defined transcription factors. Nature 476:220PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Davila J, Chanda S, Ang CE et al (2013) Acute reduction in oxygen tension enhances the induction of neurons from human fibroblasts. J Neurosci Methods 216:104PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Yoo AS, Sun AX, Li L et al (2011) MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:228PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Victor MB, Richner M, TO H et al (2014) Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron 84:311PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Faedo A, Laporta A, Segnali A et al (2017) Differentiation of human telencephalic progenitor cells into MSNs by inducible expression of Gsx2 and Ebf1. Proc Natl Acad Sci U S A 114:1234CrossRefGoogle Scholar
  84. 84.
    Mattis VB, Tom C, Akimov S et al (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet 24(11):3257–3271PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Park IH, Arora N, Huo H et al (2008) Disease-specific induced pluripotent stem cells. Cell 134:877PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Camnasio S, Delli Carri A, Lombardo A et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 46:41PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Mateizel I, De Temmerman N, Ullmann U et al (2006) Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 21:503PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Niclis JC, Trounson A, Dottori M et al (2009) Human embryonic stem cell models of Huntington disease. Reprod Biomed Online 19:106PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Jacquet L, Neueder A, Földes G et al (2015) Three Huntington’s disease specific mutation-carrying human embryonic stem cell lines have stable number of CAG repeats upon in vitro differentiation into cardiomyocytes. PLoS One 10:e0126860PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Bradley CK, Scott HA, Chami O et al (2010) Derivation of Huntington’s disease-affected human embryonic stem cell lines. Stem Cells Dev 20:495PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Dumevska B, McKernan R, Goel D et al (2016) Derivation of Huntington disease affected Genea017 human embryonic stem cell line. Stem Cell Res 16:493PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Dumevska B, Main H, McKernan R et al (2016) Derivation of Huntington disease affected Genea018 human embryonic stem cell line. Stem Cell Res 16:423PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Dumevska B, Peura T, McKernan R et al (2016) Derivation of Huntington disease affected Genea020 human embryonic stem cell line. Stem Cell Res 16:430PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Dumevska B, Chami O, McKernan R et al (2016) Derivation of Huntington disease affected Genea046 human embryonic stem cell line. Stem Cell Res 16:446PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Dumevska B, McKernan R, Hu J et al (2016) Derivation of Huntington disease affected Genea089 human embryonic stem cell line. Stem Cell Res 16:434PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Dumevska B, Schaft J, McKernan R et al (2016) Derivation of Huntington disease affected Genea090 human embryonic stem cell line. Stem Cell Res 16:519PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Dumevska B, Schaft J, McKernan R et al (2016) Derivation of Huntington disease affected Genea091 human embryonic stem cell line. Stem Cell Res 16:449PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Swami M, Hendricks AE, Gillis T et al (2009) Somatic expansion of the Huntington’s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 18:3039PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Greenamyre JT, Penney JB, Young AB et al (1985) Alterations in l-glutamate binding in Alzheimer’s and Huntington’s diseases. Science 227:1496PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Bezprozvanny I, Hayden MR (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 322:1310PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Cepeda C, Itri JN, Flores-Hernández J et al (2001) Differential sensitivity of medium-and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur J Neurosci 14:1577PubMedCrossRefGoogle Scholar
  102. 102.
    Laforet GA, Sapp E, Chase K et al (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci 21:9412CrossRefGoogle Scholar
  103. 103.
    Zeron MM, Fernandes HB, Krebs C et al (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington’s disease. Mol Cell Neurosci 25:469PubMedCrossRefGoogle Scholar
  104. 104.
    Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276PubMedCrossRefGoogle Scholar
  105. 105.
    Seriola A, Spits C, Simard JP et al (2011) Huntington’s and myotonic dystrophy hESCs: down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. Hum Mol Genet 20:176CrossRefPubMedGoogle Scholar
  106. 106.
    An MC, Zhang N, Scott G et al (2012) Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11:253PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Chae JI, Kim DW, Lee N et al (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington’s disease patient. Biochem J 446:359PubMedCrossRefGoogle Scholar
  108. 108.
    Khakh BS, Sofroniew MV (2014) Astrocytes and Huntington’s disease. ACS Chem Neurosci 5:494PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    McQuade LR, Balachandran A, Scott HA et al (2014) Proteomics of Huntington’s disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances. J Proteome Res 13:5648PubMedCrossRefGoogle Scholar
  110. 110.
    Garitaonandia I, Amir H, Boscolo FS et al (2015) Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions. PLoS One 10:e0118307PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Scherzinger E, Lurz R, Turmaine M et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Feyeux M, Bourgois-Rocha F, Redfern A et al (2012) Early transcriptional changes linked to naturally occurring Huntington’s disease mutations in neural derivatives of human embryonic stem cells. Hum Mol Genet 21:3883PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Ring KL, An MC, Zhang N et al (2015) Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human Huntington’s disease neural stem cells. Stem Cell Reports 5:1023PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Puri MC, Nagy A (2012) Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells 30:10PubMedCrossRefGoogle Scholar
  115. 115.
    Narsinh KH, Plews J, Wu JC (2011) Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? Mol Ther 19:635PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Polo JM, Liu S, Figueroa ME et al (2010) Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28:848PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Kim K, Doi A, Wen B et al (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467:285PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Urbach A, Benvenisty N (2009) Studying early lethality of 45,XO (Turner’s syndrome) embryos using human embryonic stem cells. PLoS One 4:e4175PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Panopoulos AD, Ruiz S, Izpisua Belmonte JC (2011) iPSCs: induced back to controversy. Cell Stem Cell 8:347PubMedCrossRefGoogle Scholar
  120. 120.
    Yusa K, Rad R, Takeda J et al (2009) Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 6:363PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Warren L, Manos PD, Ahfeldt T et al (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Tachibana M, Amato P, Sparman M et al (2013) Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153:1228PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Briggs R, King TJ (1952) Transplantation of living nuclei from blastula cells into enucleated frogs’ eggs. Proc Natl Acad Sci U S A 38:455PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Hayashi K, Saitou M (2013) Generation of eggs from mouse embryonic stem cells and induced pluripotent stem cells. Nat Protoc 8:1513PubMedCrossRefGoogle Scholar
  125. 125.
    Mattis VB, Svendsen CN (2017) Modeling Huntington′s disease with patient-derived neurons. Brain Res 1656:76–87PubMedCrossRefGoogle Scholar
  126. 126.
    Gore A, Li Z, Fung HL et al (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471:63PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Christian M, Cermak T, Doyle EL et al (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 93:1156PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Jiang W, Bikard D, Cox D et al (2013) RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31:233PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    An MC, O’Brien RN, Zhang N et al (2014) Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr 6.  https://doi.org/10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a
  131. 131.
    Ruzo A, Croft GF, Metzger JJ, Galgoczi S, Gerber LJ, Pellegrini C, Wang H Jr, Fenner M, Tse S, Marks A, Nchako C, Brivanlou AH (2018) Chromosomal instability during neurogenesis in Huntington’s disease. Development 145:2PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Lee JM, Ramos EM, Lee JH et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Boulting GL, Kiskinis E, Croft GF et al (2011) A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 29:279PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Hu B-Y, Weick JP, Yu J et al (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 107:4335PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Naphade S, Embusch A, Madushani KL, Ring KL, Ellerby LM (2018) Altered expression of matrix metalloproteinases and their endogenous inhibitors in a human isogenic stem cell model of Huntington’s disease. Front Neurosci 11:736PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Juopperi TA, Kim WR, Chiang CH et al (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol Brain 5:17PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Niclis JC, Pinar A, Haynes JM et al (2013) Characterization of forebrain neurons derived from late-onset Huntington’s disease human embryonic stem cell lines. Front Cell Neurosci 7:37PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Nguyen GD, Gokhan S, Molero AE et al (2013) Selective roles of normal and mutant huntingtin in neural induction and early neurogenesis. PLoS One 8:e64368PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Conforti P, Besusso D, Bocchi VD, Faedo A, Cesana E, Rossetti G, Ranzani V, Svendsen CN, Thompson LM, Toselli M, Biella G, Pagani M, Cattaneo E (2018) Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes. Proc Natl Acad Sci U S A. 115:4CrossRefGoogle Scholar
  140. 140.
    Jackson M, Gentleman S, Lennox G et al (1995) The cortical neuritic pathology of Huntington’s disease. Neuropathol Appl Neurobiol 21:18PubMedCrossRefGoogle Scholar
  141. 141.
    Mihm MJ, Amann DM, Schanbacher BL et al (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis 25:297PubMedCrossRefGoogle Scholar
  142. 142.
    van der Burg JM, Winqvist A, Aziz NA et al (2011) Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis 44:1PubMedCrossRefGoogle Scholar
  143. 143.
    Shi Y, Kirwan P, Livesey FJ (2012) Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7:1836PubMedCrossRefGoogle Scholar
  144. 144.
    Spence JR, Mayhew CN, Rankin SA et al (2011) Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470:105PubMedCrossRefGoogle Scholar
  145. 145.
    Mummery CL, Zhang J, Ng ES et al (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111:344PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457PubMedCrossRefGoogle Scholar
  147. 147.
    Bar-Nur O, Caspi I, Benvenisty N (2012) Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 4:180PubMedCrossRefGoogle Scholar
  148. 148.
    Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, Huh CJ, Zhang B, Davidson BL, Yang XW, Yoo AS (2018) Striatal neurons directly converted from Huntington’s disease patient fibroblasts recapitulate age-associated disease phenotypes. Nat Neurosci.  https://doi.org/10.1038/s41593-018-0075-7
  149. 149.
    Davis GC, Williams AC, Markey SP et al (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1:249PubMedCrossRefGoogle Scholar
  150. 150.
    Langston JW, Ballard P, Tetrud JW et al (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979PubMedCrossRefGoogle Scholar
  151. 151.
    Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Shin JW, Kim KH, Chao MJ et al (2016) Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet 25(20):4566–4576PubMedPubMedCentralGoogle Scholar
  153. 153.
    Raab S, Klingenstein M, Liebau S et al (2014) A comparative view on human somatic cell sources for iPSC generation. Stem Cells Int 2014:768391PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Sareen D, Saghizadeh M, Ornelas L et al (2014) Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med 3:1002PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Hill KA, Buettner VL, Halangoda A et al (2004) Spontaneous mutation in Big Blue mice from fetus to old age: tissue-specific time courses of mutation frequency but similar mutation types. Environ Mol Mutagen 43:110PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Hoang ML, Kinde I, Tomasetti C et al (2016) Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc Natl Acad Sci U S A 113:9846PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    El Hokayem J, Cukier HN, Dykxhoorn DM (2016) Blood derived induced pluripotent stem cells (iPSCs): benefits, challenges and the road ahead. J Alzheimers Dis Parkinsonism 6.  https://doi.org/10.4172/2161-0460.1000275
  158. 158.
    Kang E, Wang X, Tippner-Hedges R et al (2016) Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell 18:625PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Abulencia A, Acosta D, Adelman J et al (2006) Direct search for Dirac magnetic monopoles in pp collisions at square root s = 1.96 TeV. Phys Rev Lett 96:201801PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Seo H, Sonntag KC, Isacson O (2004) Generalized brain and skin proteasome inhibition in Huntington’s disease. Ann Neurol 56:319PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Varani K, Abbracchio MP, Cannella M et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. FASEB J 17:2148PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Precious SV, Kelly CM, Reddington AE et al (2016) FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation. Exp Neurol 282:9PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Straccia M, Carrere J, Rosser AE et al (2016) Human t-DARPP is induced during striatal development. Neuroscience 333:320PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Mayshar Y, Ben-David U, Lavon N et al (2010) Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7:521PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Taapken SM, Nisler BS, Newton MA et al (2011) Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat Biotechnol 29:313PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Närvä E, Autio R, Rahkonen N et al (2010) High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 28:371PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Amps K, Andrews PW, Anyfantis G et al (2011) Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 29:1132PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Maitra A, Arking DE, Shivapurkar N et al (2005) Genomic alterations in cultured human embryonic stem cells. Nat Genet 37:1099PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Müller FJ, Schuldt BM, Williams R et al (2011) A bioinformatic assay for pluripotency in human cells. Nat Methods 8:315PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Hochedlinger K, Yamada Y, Beard C et al (2005) Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121:465PubMedCrossRefGoogle Scholar
  171. 171.
    Park ET, Gum JR, Kakar S et al (2008) Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer 122:1253PubMedCrossRefGoogle Scholar
  172. 172.
    Ghaleb AM, Nandan MO, Chanchevalap S et al (2005) Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res 15:92PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Kuttler F, Mai S (2006) c-Myc, genomic instability and disease. Genome Dyn 1:171PubMedCrossRefGoogle Scholar
  174. 174.
    Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313PubMedCrossRefGoogle Scholar
  175. 175.
    Seki T, Yuasa S, Oda M et al (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7:11PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Yu J, Hu K, Smuga-Otto K et al (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324:797PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Mangiarini L, Sathasivam K, Mahal A et al (1997) Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet 15:197PubMedCrossRefGoogle Scholar
  178. 178.
    Gonitel R, Moffitt H, Sathasivam K et al (2008) DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A 105:3467PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Shelbourne PF, Keller-McGandy C, Bi WL et al (2007) Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet 16:1133CrossRefPubMedGoogle Scholar
  180. 180.
    Jonson I, Ougland R, Klungland A et al (2013) Oxidative stress causes DNA triplet expansion in Huntington’s disease mouse embryonic stem cells. Stem Cell Res 11:1264CrossRefPubMedGoogle Scholar
  181. 181.
    Osafune K, Caron L, Borowiak M et al (2008) Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 26:313PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Miller JD, Ganat YM, Kishinevsky S et al (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13:691PubMedPubMedCentralCrossRefGoogle Scholar
  183. 183.
    Nopoulos PC, Aylward EH, Ross CA et al (2011) Smaller intracranial volume in prodromal Huntington’s disease: evidence for abnormal neurodevelopment. Brain 134:137PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Blockx I, De Groof G, Verhoye M et al (2012) Microstructural changes observed with DKI in a transgenic Huntington rat model: evidence for abnormal neurodevelopment. Neuroimage 59:957PubMedPubMedCentralCrossRefGoogle Scholar
  185. 185.
    Molero AE, Arteaga-Bracho EE, Chen CH et al (2016) Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington’s disease. Proc Natl Acad Sci U S A 113:5736PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Guo X, Disatnik MH, Monbureau M et al (2013) Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest 123:5371PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Lu XH, Mattis VB, Wang N et al (2014) Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease. Sci Transl Med 6:268ra178CrossRefPubMedGoogle Scholar
  188. 188.
    Charbord J, Poydenot P, Bonnefond C et al (2013) High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells 31:1816PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Orqueda AJ, Giménez CA, Pereyra-Bonnet F (2016) iPSCs: a minireview from bench to bed, including organoids and the CRISPR system. Stem Cells Int 2016:5934782PubMedPubMedCentralCrossRefGoogle Scholar
  190. 190.
    Ehrnhoefer DE, Butland SL, Pouladi MA et al (2009) Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2:123PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Lippmann ES, Azarin SM, Kay JE et al (2012) Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol 30:783PubMedPubMedCentralCrossRefGoogle Scholar
  192. 192.
    Qian T, Maguire SE, Canfield SG, Bao X, Olson WR, Shusta EV, Palecek SP (2017) Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells. Sci Adv. 3:11CrossRefGoogle Scholar
  193. 193.
    Chandrasekaran A, Avci HX, Leist M et al (2016) Astrocyte differentiation of human pluripotent stem cells: new tools for neurological disorder research. Front Cell Neurosci 10:215PubMedPubMedCentralCrossRefGoogle Scholar
  194. 194.
    Rosas HD, Doros G, Bhasin S et al (2015) A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease. Ann Clin Transl Neurol 2:756PubMedPubMedCentralCrossRefGoogle Scholar
  195. 195.
    Liot G, Valette J, Pépin J et al (2016) Energy defects in Huntington’s disease: why “in vivo” evidence matters. Biochem Biophys Res Commun 483(4):1084–1095PubMedPubMedCentralCrossRefGoogle Scholar
  196. 196.
    Umbach JA, Adams KL, Gundersen CB et al (2012) Functional neuromuscular junctions formed by embryonic stem cell-derived motor neurons. PLoS One 7:e36049PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    Xiang Y, Tanaka Y, Patterson B, Kang YJ, Govindaiah G, Roselaar N, Cakir B, Kim KY, Lombroso AP, Hwang SM, Zhong M, Stanley EG, Elefanty AG, Naegele JR, Lee SH, Weissman SM, Park IH (2017) Fusion of regionally specified hPSC-derived organoids models human brain development and interneuron migration. Cell Stem Cell 21:3CrossRefGoogle Scholar
  198. 198.
    Darbinyan A, Pozniak P, Darbinian N et al (2013) Compartmentalized neuronal cultures. Methods Mol Biol 1078:147PubMedPubMedCentralCrossRefGoogle Scholar
  199. 199.
    Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32:760PubMedPubMedCentralCrossRefGoogle Scholar
  200. 200.
    Weick JP, Johnson MA, Skroch SP et al (2010) Functional control of transplantable human ESC-derived neurons via optogenetic targeting. Stem Cells 28:2008PubMedPubMedCentralCrossRefGoogle Scholar
  201. 201.
    Lancaster MA, Renner M, Martin CA et al (2013) Cerebral organoids model human brain development and microcephaly. Nature 501:373PubMedPubMedCentralCrossRefGoogle Scholar
  202. 202.
    Fatehullah A, Tan SH, Barker N (2016) Organoids as an in vitro model of human development and disease. Nat Cell Biol 18:246PubMedPubMedCentralCrossRefGoogle Scholar
  203. 203.
    Paşca AM, Sloan SA, Clarke LE et al (2015) Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods 12:671PubMedPubMedCentralCrossRefGoogle Scholar
  204. 204.
    Crotti A, Benner C, Kerman BE et al (2014) Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 17:513PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Huang B, Wei W, Wang G et al (2015) Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron 85:1212PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Mertens J, Paquola AC, Ku M et al (2015) Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell 17(6):705–718PubMedPubMedCentralCrossRefGoogle Scholar
  207. 207.
    Huh CJ, Zhang B, Victor MB et al (2016) Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. Elife 5.  https://doi.org/10.7554/eLife.18648
  208. 208.
    Bran S, Murray WA, Hirsch IB et al (1995) Long QT syndrome during high-dose cisapride. Arch Intern Med 155:765PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Charlene Geater
    • 1
    • 2
  • Sarah Hernandez
    • 2
    • 3
  • Leslie Thompson
    • 1
    • 2
    • 3
  • Virginia B. Mattis
    • 4
  1. 1.Department of Psychiatry and Human BehaviorUniversity of California-IrvineIrvineUSA
  2. 2.Sue and Bill Gross Stem Cell Research CenterUniversity of California-IrvineIrvineUSA
  3. 3.Department of Neurobiology and BehaviorUniversity of California-IrvineIrvineUSA
  4. 4.Cedars-Sinai Medical CenterBoard of Governor’s Regenerative Medicine Institute and Biomedical SciencesLos AngelesUSA

Personalised recommendations